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Abstract We reviewed clinical studies performed with the
Bioenterics intragastric balloon (BIB) to promote weight
loss. Thirty studies were included [18 prospective (5 random-
ized), 12 retrospective], totaling 4,877 patients. Only one of
three sham-controlled trials found a significantly higher
weight loss with the BIB vs the sham procedure plus
exhaustive follow-up. In nonrandomized studies, weight loss
with the BIB averaged 17.8 kg (range, 4.9–28.5),
corresponding to BMI changes of 4.0–9.0 kg/m2. Comorbid-
ities resolved or improved in 52–100% of patients. Best
short-term results were observed in patients devoid of binge
eating disorder with a BMI in the 30.0–40.0 kg/m2 range; the
BIB also helped to prepare superobese patients for bariatric
surgery. Severe complications were exceptional (gastric
perforation and intestinal obstruction; 0.2% each); digestive
intolerance prompted early BIB removal in 2.5% of
patients. Long-term (≥2 years) results are awaited, as well
as well-designed studies to define the best indications for
this therapy.
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Introduction
Intragastric balloons were proposed as an aid to promote
weight loss more than 20 years ago, but original models
were rapidly abandoned because they were ineffective and
potentially harmful. In 1987, an expert meeting was held to
define the requirements for an “ideal” intragastric balloon
and the settings of a weight loss program using this
technique [1]. Since then, three models of intragastric
balloon have been made commercially available: the first
one [Bioenterics intragastric balloon (BIB)] was filled with
liquid and it has been implanted in tens of thousands of
patients; two different, air-filled, models (Heliosphere Bag
and Endogast) have recently become available. The
Endogast presents the particularity of requiring a combined
endoscopic and surgical insertion procedure (an inflation/
deflation port is attached to the balloon and implanted
subcutaneously).
Here, we review the experience published about the
liquid-filled BIB used as an adjunct for weight loss
promotion in humans; readers interested in air-filled
balloons are referred to the few recent articles published
about these devices [2–4].
Methods
A review of the literature was performed by searching
PubMed for the period from January 1995 to February
2008, with the search terms intragastric and balloon. A total
of 157 studies were found, of which 127 studies were
excluded because they did not assess weight loss in humans
(n=82), included ≤15 patients (n=20), contained no
original data (n=9), were not available in the English
language (n=7), contained no abstract (n=6), or used a
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balloon different from the BIB (n=3). This resulted in a
total of 30 studies to be included in this review [5–34].
Practical Considerations
Treatment with the BIB should be proposed in the setting of
a multidisciplinary team, after failure of conservative
measures and exclusion of a hormonal or genetic cause
for obesity. Candidates for this treatment must understand
that the BIB is a temporary aid to promote weight loss.
Indications retained for BIB therapy are generally based on
criteria of body mass index (BMI) and the presence or
absence of comorbidities, but these criteria vary between
studies. Compared to recommendations for bariatric surgery
and weight-loss drugs released by the US National Health
Institutes [35], criteria used for BIB therapy generally
correspond to a disease severity that is intermediate
between those stated for these two therapeutic options.
Commonly cited criteria for BIB therapy include a BMI
comprised (in kilograms per square meter) between (1) 27.0
and 29.9, in association with severe comorbidities that will
likely improve with weight loss (typically insulin-requiring
diabetes); (2) 30.0 and 34.9, with comorbidities; (3) 35.0
and 39.9 without comorbidities; (4) or ≥40, mostly as a
preparation for bariatric surgery. Contraindications are
listed in Table 1.
Balloon insertion and removal are performed under
conscious sedation or general anesthesia. Briefly, (1) upper
gastrointestinal endoscopy is performed to detect possible
contraindications to BIB insertion; (2) immediately after
endoscope removal, the BIB placement assembly is inserted
through the mouth into the stomach (if the procedure is
performed under conscious sedation, asking the patient to
swallow may facilitate catheter’s progression or, if it is
performed under general anesthesia with tracheal intuba-
tion, temporary deflation of the tracheal balloon may be
helpful); (3) the balloon is positioned in the fundus under
endoscopic control, the chuck is removed from the insertion
catheter, and the balloon is inflated by injecting saline
mixed with 10-ml methylene blue into the catheter; (4)
finally, once the desired volume has been injected, the
balloon is released by a short pull on the catheter. The BIB
should be removed after a maximum of 6 months because
beyond this period, the risk of spontaneous balloon
deflation significantly increases.
Early complications include epigastric pain and nausea
that develop in a majority of patients a few hours after BIB
insertion. Tropisetron has been shown in a randomized trial
to be most effective to reduce the incidence of vomiting
during the first 24 h following BIB insertion [32]. This
side-effect has been overlooked in many studies because it
is usually transient, but patients should be well aware of this
possibility and, if BIB insertion is performed on an ambu-
latory basis, patients should be instructed to ask for medical
advice in case of prolonged symptoms (due to the risk of
dehydration). Persistence of these symptoms for ≥1 week has
required BIB removal in up to 7% of cases [12].
Balloon removal requires specific material that should be
available as soon as a program of BIB therapy is started
[33]. A randomized study has shown that a double-channel
endoscope was superior to a single-channel endoscope in
terms of number of lost balloons, balloon retrieval duration,
and patient discomfort (the BIB was seized with both grasping
forceps and a snare) [16]. However, in the present author’s
experience, the use of dedicated ancillary devices to fully
empty and then grasp the balloon consistently allows BIB
removal, even with a single-channel endoscope [33]. None-
theless, a double-channel endoscope may be useful because
gastric content may be abundant even if a liquid diet has
been prescribed for the 24 h preceding BIB removal.
Results
Short-term Weight Loss
Three randomized studies have compared short-term weight
loss with the BIB vs a sham procedure. In a study including
32 patients (mean BMI, 43.7 kg/m2) [19], the BMI had
significantly decreased 3 months after BIB insertion but not
after the sham procedure (Fig. 1). After crossover between
groups, the BMI remained almost stable in patients who
had the BIB extracted, while it significantly decreased in
patients who had received the BIB for the first time.
Authors’ findings apparently were in contradiction with
those of two other trials, which found similar weight losses
Table 1 Contraindications generally cited to the placement of
Bioenterics intragastric balloon
Contraindications
Absolute contraindications
Previous gastric surgery
Hiatal hernia ≥5 cm
Coagulation disorder
Potentially bleeding lesion of the upper gastrointestinal tract
Pregnancy or desire to become pregnant, breast-feeding
Alcoholism or drug addiction
Severe liver disease
Any contra-indication to endoscopy
Relative contraindications
Previous abdominal surgery
Hiatal hernia, esophagitis
Crohn’s disease
Intake of nonsteroidal anti-inflammatory drugs
Psychiatric disorders
1612 OBES SURG (2008) 18:1611–1617
with the BIB and the sham procedure (1) in 43 patients with
a mean BMI of 43.3 kg/m2 (weight losses, 12.9 vs 11.2 kg,
respectively) [23] and (2) in 21 patients with a mean BMI
of 50.4 kg/m2 (weight losses, 12.7 vs 8.9 kg, respectively)
[22]. The authors estimated that the good results observed
with the sham treatment could have been related to the
“exhaustive periodic assessment of dietetic habit” [22].
Absolute weight loss was also available in 22 nonrandom-
ized studies included in this review: among 4,371 patients,
mean weight loss with the BIB was 17.8 kg (extremes of the
means, 4.9–28.5 kg) [5–13, 15, 17, 18, 20, 21, 25–31, 34].
It is important to inform candidates for BIB insertion that
20–40% of patients fail to achieve a significant weight loss
(often defined as ≥10% baseline weight or ≥25% excess
weight) [20, 23, 24]. Such failures may be related to the
request of early BIB removal by patients who present a
digestive or psychological intolerance to the BIB (103 of
4,361 patients for whom the information was available;
2.4%), to the early vanishing of anticipated effects on
hunger and early satiety, or to patient’s adaptation of food
intake. Endoscopic adjustment of the BIB-filling volume
has been proposed to palliate these problems [23], but it has
been abandoned due to technical difficulties [11].
Evolution of Body Weight Loss at 1 Year
After BIB Removal
Two studies (one randomized, one uncontrolled) totaling
143 patients have reported that, 1 year after BIB removal,
patients had regained 41% and 28% (mean values,
respectively) of the absolute weight loss observed at BIB
removal [20, 23]. Herve et al. also detailed that 56% of
patients had ≥20% excess weight loss 1 year after BIB
removal (compared to 74% at the time of BIB removal),
and Mathus-Vliegen et al. detailed that the proportion of
patients with ≥10% baseline weight loss had dropped from
75% to 47% during the year following BIB removal. A
combination of therapies (to induce weight loss in refrac-
tory patients and then maintain it) might prove valuable: in
a nonrandomized controlled trial [36], a 6-month course of
sibutramine after BIB removal allowed limiting weight
regain at 1.8 kg compared to 6.8 kg in patients receiving
no weight-loss medication (values 1 year after BIB removal,
P<0.001).
Specific Aspects of BIB Therapy
Nonrandomized studies have yielded interesting informa-
tion in various aspects:
Weight Loss According to BMI Categories
Six months after BIB insertion, the absolute weight loss
tends to be higher in patients with BMI higher vs lower
than 40 kg/m2 (mean, 22.5 vs 12.5 kg) [29]. However,
when the percentage of excess weight loss was considered,
it was significantly higher in patients of lower compared to
higher BMI categories, and it even attained a median of
97% in women with a baseline BMI comprised between 25
and 30 kg/m2 (Fig. 2).
Fig. 1 Evolution of the body mass index (BMI) in patients
randomized to Bioenterics intragastric balloon (BIB) insertion or sham
procedure, with crossover at 3 months. P values for BMI changes over
3-month periods were <0.001 for each group during BIB therapy and
not significant during sham therapy. Adapted from Genco et al. [19]
with permission
Fig. 2 Boxplot showing the percentage of excess weight loss
6 months after insertion of the Bioenterics intragastric balloon in
323 patients. Numbers (N) of men and women are indicated separately
for each category of BMI (figures between parentheses below the X
axis). Adapted from Genco et al. [19] with permission
OBES SURG (2008) 18:1611–1617 1613
Comorbidities and Quality of Life
A large retrospective study from the Italian group for Lap-
Band has shown that, although modest, weight losses
induced by the BIB allowed resolving or improving most
comorbidities associated with obesity, in particular, respi-
ratory disorders, hypertension, diabetes, and osteoarthrop-
athy (Table 2) [18]. Unfortunately, no study has assessed
the evolution of comorbidities during follow-up after BIB
removal or potential changes in mortality after BIB
treatment. The effect of BIB therapy on obstructive sleep
apnea has been specifically studied because it poses
significant challenges to anesthesiologists during the peri-
operative period. BIB therapy in 17 obese men affected
with this syndrome (mean BMI, 55.8 kg/m2) induced a
nearly complete resolution, and this was associated with an
increase in the pharyngeal cross-sectional area [8]. No
treatment failure was observed in patients who lost >12%
body weight.
The impact of intragastric balloon therapy on the quality
of life was assessed using a validated tool in a single small
study that used an air-filled balloon: the authors reported a
significant improvement of the quality of life up to 1 month
after BIB removal (Fig. 3) [33]. Again, no follow-up data
were provided.
Use of the BIB in Specific Patient Populations
Binge eaters represent 16–30% of obese patients involved
in weight loss programs. This disorder is usually diagnosed
following an interview with a psychologist and fulfillment
of self-assessment questionnaires based on established
criteria. It might be a valuable predictor of poor results
with the BIB, as binge eaters were reported to request early
BIB removal more frequently than nonbinge eaters and,
finally, to experience lower BMI losses (3.3 vs 5.7 kg/m2,
P<0.05) [26].
Superobese (BMI>50 kg/m2) patients frequently fail to
achieve adequate weight loss after bariatric surgery and
they harbor an increased surgical risk compared to less
severely obese patients, so that preoperative weight loss has
been recommended. Three groups of authors have reported
grossly concordant results with preoperative BIB therapy:
approximately 90% of patients (mean BMI, 58–64 kg/m2)
tolerated the BIB, and they lost between 10% and 26% of
excess weight [6, 9, 34]. In the study that included controls
[9], preoperative BIB therapy was associated with a lower
rate of conversion to open surgery (0% vs 16%), shorter
operative time, and shorter postoperative hospital stay (all
P values <0.05). However, (1) the evolution of weight
during follow-up after surgery was not significantly
different in patients with or without BIB preparation and
Table 2 Comorbidities at the time of BIB removal (6 months) in a nationwide series of 2,515 patients (mean BMI, 44.4±7.8 kg/m2) treated with
the Bioenterics intragastric balloon
Comorbidity Resolution Improvementa (%) No change (%)
Criteria Incidence (%)
Hypertension (n=509) Systolic <120–130 mmHg 44.8 48.9 6.3
Diabetes (n=488) Fasting glycemia <110 mg/dL HbA1c <6% 32.8 54.4 13.1
Respiratory disorders (n=247) Absence of symptoms 83.0 17.0 0
Osteoarthropathy (n=271) Absence of pain 40.9 46.1 12.9
Dyslipidemia (n=318) Triglycerides <200 mg/dL 15.4 36.5 48.1
Others (n=176) 71.6 8.5 19.8
a Improvement was defined as lower drug dosage or shift to other therapy, excepted for the improvement of respiratory disorders defined as the
disappearance of obstructive sleep apnea syndrome with persisting tachypnea after physical activity, and that of dyslipidemia, which was
prevalently linked to normalization of tryglicerides while modification of cholesterolemia was less important. Adapted from Genco et al. [18].
Fig. 3 Evolution of the quality of life as assessed by the IWQOL-Lite
score in 17 patients (mean BMI, 34.4 kg/m2) treated with the
Bioenterics intragastric balloon (lower scores indicate better quality
of life). M0: baseline; M1 and M4, 1 and 4 months after balloon
insertion, respectively; M7, 1 month after balloon removal. Repro-
duced with permission from Mion et al. [25]
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(2) patients should be clearly informed that BIB therapy is
not a replacement for bariatric surgery (weight regain after
BIB removal may be very rapid and important in super-
obese patients) [7]. The main effect of BIB therapy (apart
from the improvement of obstructive sleep apnea) could be
a reduction in liver volume that is much more important
than that of body weight (a voluminous left hepatic lobe
may impede laparoscopic approach to the stomach) [15].
Adolescents have been included in many studies investi-
gating the BIB, but their outcome has rarely been reported
separately from that of other patients. In a large series [29],
mean BMI decrease with the BIB was similar in 21
adolescents compared to 302 adults (5.0 vs 5.3 kg/m2,
respectively), and no significant weight change occurred in
the five adolescents who were followed during 1 year after
BIB removal.
BIB-filling Volume
According to the manufacturer, the BIB may be filled with
400 to 700 ml of saline (500 to 600 ml is used in most
studies). A nonrandomized retrospective study has sug-
gested that a 600-ml filling volume could provide a higher
weight loss at the time of BIB removal compared to that
obtained with a 500-ml filling volume (12.9 vs 8.6 kg,
P<0.002) [27]. However, this result should be confirmed
since criteria for choosing the filling volume (e.g., body
height) were not stated, and the incidence of side effects
was not detailed according to filling volumes.
BIB for Selecting Among Bariatric Procedures
The “BIB test” has been proposed to predict in a particular
patient if a gastric restrictive surgical procedure would be
successful [21]. This test has been prospectively evaluated
in 40 patients (mean BMI, 46.5 kg/m2) who underwent BIB
therapy followed by laparoscopic adjustable gastric banding
[11]. Successful treatments were defined as ≥10% baseline
weight loss with the BIB, and a further weight loss of ≥15%
with surgery. This study found that the “BIB test” had
mixed predictive values for further weight loss with
banding (positive and negative predictive values; 56%
and 73%, respectively), but the final weight loss was higher
in patients with successful vs unsuccessful BIB therapy
(12.4 vs 9.0 kg/m2 at 18 months, respectively; P=0.03).
BIB as a First Step Toward Bariatric Surgery
BIB therapy has been suggested to facilitate the acceptance
of bariatric surgery: among 140 patients who had initially
refused bariatric surgery but had agreed for BIB therapy,
32% had undergone bariatric surgery at a mean follow-up
of 18 months [24]. Bariatric surgery was most frequent
(64%) among patients who had successfully lost weight
with the BIB (and, hence, had experienced associated
benefits) but who had then regained weight, while it was
mixed (33%) in those who had not significantly lost weight,
and very low (7%) in those who had maintained a
successful weight loss during follow up.
Complications
Reporting of complications was extremely variable between
studies; severe complications could be analyzed in 20
studies, totaling 4,240 patients [5, 8–10, 12–15, 17–21, 23,
25–27, 29–31, 34]. Three deaths were reported (treatment-
related death rate, 0.07%), due to gastric perforation in
patients with previous Nissen fundoplication (n=2) and
bronchoaspiration following BIB insertion (n=1). Gastric
perforation was reported in a total of nine patients (0.21%)
(five of them had a previous history of gastric surgery).
Bowel obstruction required surgical, endoscopic, or com-
bined BIB removal in seven (0.17%) patients. Early
endoscopic BIB removal (mainly for digestive intolerance)
was reported in 103 (2.43%) patients and hypokalemia in
20 (0.47%) patients.
Reporting of less severe complications was less consis-
tent among studies, probably because these can usually be
managed by phone calls or during scheduled visits.
Abdominal pain after the first week following BIB insertion
has been reported in 0–15.9% of cases [5, 27]. Spontaneous
BIB deflation has been reported in extremely varying
proportions of cases (3–23%) in different studies [12, 20,
21], likely due to the practice in some centers of
maintaining balloons in place beyond the 6-month recom-
mended period. Spontaneous BIB deflation may be
detected by repeated ultrasonography at fixed time intervals
(although a learning curve does exist for this technique and
its cost-effectiveness is not established) [14], green color-
ation of the urines (methylene blue present in the BIB is
absorbed and excreted by the kidneys in case of leakage),
or a sudden change of patient’s tolerance to food intake.
Most deflated balloons were spontaneously eliminated, but
particular attention should be paid in patients at increased
risk for bowel obstruction (e.g., previous history of
abdominal surgery). Gastroduodenal ulcers (often asymp-
tomatic) were reported in 0.4% of patients. Esophagitis has
been specifically analyzed by Rossi et al. in 121 patients:
esophagitis was present at the time of BIB insertion in 15%
of patients, and its incidence and severity were slightly
increased (up to 18.2%) with the BIB, even if proton pump
inhibitors were prescribed “on-demand” [28].
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Conclusion
The BIB was found to be effective for promoting short-term
weight loss in about two thirds of patients and safe
provided that contraindications were observed. Mean
weight loss was 17.8 kg, with higher absolute values
observed in higher BMI categories. BIB therapy was
followed by a significant improvement in comorbidities at
short term. Patients with a BMI comprised between 30.0
and 39.9 kg/m2 who have failed to lose weight with other
approaches represented the best candidates for BIB therapy,
as well as superobese patients in preparation for bariatric
surgery. Although the BIB has been available for >10 years,
data are still lacking about the success of weight mainte-
nance ≥2 years after BIB removal and about predictive
factors for short- and long-term success. Improvements are
still awaited, in particular to soften early digestive intoler-
ance (this is a significant obstacle to ambulatory BIB
insertion in many centers) and to optimize balloon-filling
volume/treatment duration.
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